Ianalumab (FUT8-KO)  (Synonyms: VAY-736 (FUT8-KO))

Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

TNFRSF13C/BAFFR/CD268

Ianalumab (FUT8-KO) (10 μg/mL) blocks the activation of the alternative NF-κB pathway in BAFF-mediated primary CLL B cells and primary CLL B cells treated with Ibrutinib (HY-10997) by inhibiting p100 degradation and p52 nuclear translocation^[2].
Ianalumab (FUT8-KO) (0.1-10 μg/mL) induces higher IFN-γ levels in primary CLL NK cells than Obinutuzumab (HY-P9910) at a concentration of 10 μg/mL^[2].
Ianalumab (FUT8-KO) induces TNF-α production in primary monocytes and monocyte-derived macrophages from patients with chronic lymphocytic leukemia (CLL)^[2].
Ianalumab (FUT8-KO) induces antibody-dependent cellular phagocytosis of primary chronic lymphocytic leukemia (CLL) B cells by monocyte-derived macrophages, at levels comparable to those of clinically relevant CD20-targeting antibodies^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ianalumab (FUT8-KO) (100 mg/kg; Retro-orbital injection; once weekly; 2 weeks) reduces circulating chronic lymphocytic leukemia cell counts and percentages in Eμ-TCL1 transgenic mice, with effects sustained for at least 80 days^[2].
Ianalumab (FUT8-KO) (10 mg/kg; Retro-orbital injection; once weekly; up to 6 weeks) improves survival and reduces chronic lymphocytic leukemia burden in SCID mice engrafted with leukemic Eμ-TCL1 splenocytes compared to ibrutinib monotherapy^[2].
Combination treatment withIanalumab (FUT8-KO) (10 mg/kg; Retro-orbital injection; once weekly; up to 6 weeks) and ibrutinib significantly improves survival and reduces chronic lymphocytic leukemia burden in SCID mice engrafted with leukemic Eμ-TCL1 splenocytes compared to either monotherapy alone^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

115650  [NCBI]

Q96RJ3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.44 kDa

Liquid

Colorless to light yellow

[Ianalumab (FUT8-KO)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized Human BAFFR/TNFRSF13C, Fc tag can bind Ianalumab (FUT8-KO). The EC₅₀ for this effect is 4.477 ng/mL.

• [1]. Dörner T, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641-647.

  [2]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019;3(3):447-460.  [Content Brief]